Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905999 | 0.86 | ALDH1A1 (0.44) | KDM4EGAAALDH1A1GLALMNA | |
| SCHEMBL28244743 | 0.86 | ALDH1A1 (0.44) | KDM4EGAAALDH1A1GLALMNA | |
| SCHEMBL16836475 | 0.86 | ALDH1A1 (0.47) | KDM4EGAAALDH1A1GLALMNA | |
| SCHEMBL1554575 | 0.85 | KDM4E (0.64) | KDM4EGAAALDH1A1GLALMNA | |
| SCHEMBL30465506 | 0.83 | KDM4C (0.49) | KDM4EGAAALDH1A1GLAL3MBTL1 | |
| SCHEMBL668446 | 0.83 | KDM4C (0.49) | KDM4EGAAALDH1A1GLAL3MBTL1 | |
| SCHEMBL334854 | 0.83 | CA12 (0.47) | KDM4EGAAALDH1A1GLALMNA | |
| SCHEMBL29416299 | 0.82 | KDM4E (0.70) | KDM4EGAAALDH1A1GLALMNA | |
| SCHEMBL68952 | 0.82 | KDM4E (0.70) | KDM4EGAAALDH1A1GLALMNA | |
| SCHEMBL3966553 | 0.81 | SIRT3 (0.59) | KDM4EGAAALDH1A1GLACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727943-A1 | INHIBITORS OF MET KINASE | Celyn Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025087375-A1 | NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE AGONIST AND USE THEREOF | 南京瑞初医药有限公司 | 2025-05-01 | — | — | WO | disclosed |
| WO-2024259060-A1 | INHIBITORS OF MET KINASE | KINNATE BIOPHARMA INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4329881-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | Vanqua Bio, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117642404-A | Small molecule modulators of glucocerebrosidase activity and uses thereof | 凡况生化公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2023107547-A2 | AZETIDINE AND SPIROAZETIDINE COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107547-A2 | AZETIDINE AND SPIROAZETIDINE COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-4168408-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2023-04-26 | — | — | EP | disclosed |
| CN-115667256-A | Compounds for treating diseases and methods of treating diseases | 艾特里提治疗有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2022232383-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2021253091-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021253091-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2021-12-23 | — | — | WO | disclosed |
| US-11155547-B1 | Compounds for and methods of treating diseases | Alterity Therapeutics Limited (AU) | 2021-10-26 | — | — | US | disclosed |
| US-11155547-B1 | Compounds for and methods of treating diseases | Alterity Therapeutics Limited (AU) | 2021-10-26 | — | — | US | disclosed |
| US-5173496-A | Antiinflammatory agents | ICI PHARMA (FR) | 1992-12-22 | — | — | US | disclosed |
| EP-0284174-B1 | THERAPEUTIC PREPARATIONS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-29 | — | — | EP | disclosed |
| EP-0284174-A1 | Therapeutic preparations | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-09-28 | — | — | EP | disclosed |
| US-4089960-A | Antiemetic, psychosomatic and antipsychotic heterocyclic pyridine carboxamides | CIBA-GEIGY CORPORATION (US) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155547-B1 | Compounds for and methods of treating diseases | HTT, SNCA, PARK7 | KDM4E 1820/4885GAA 23/4885ALDH1A1 2721/4885 |
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | KDM4E 3762/4885GAA 2/4885ALDH1A1 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.